Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1271274

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1271274

Herpes Simplex Virus Treatment Market, By Drug Type, By Route of Administration, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

PUBLISHED:
PAGES: 171 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

The herpes simplex virus (HSV) is a viral infection that causes genital and oral herpes. It is a very contagious virus that causes infections. There are two types of HSV, such as HSV-1 and HSV-2. There is no cure for genital herpes, however, daily use of antiviral medicines can prevent or shorten outbreaks, and reduce the chance of spreading it to others. Thus, there is an increasing demand for safe and effective herpes simplex virus treatment worldwide.

Market Dynamics:

Increase in prevalence of infections of the herpes simplex virus, rise in number of clinical trials, increase in demand for safe and effective HSV treatment, and increase in awareness among people about herpes simplex virus are major factors expected to augment the growth of the global herpes simplex virus treatment market over the forecast period.

For instance, in October 2021, United BioPharma, Shanghai Public Health Clinical Centre, and Department of Microbiology (Cheng Kung University) and Immunology teamed up to investigate the efficacy of UB-621, a best-in-class long-acting medicine for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and 2). Moreover, the World Health Organization (WHO) and partners support research to develop new strategies for prevention and control of HSV infections.

Key features of the study:

  • This report provides in-depth analysis of the global herpes simplex virus treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global herpes simplex virus treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Fresenius SE & Co. KgaA, Glenmark Pharmaceuticals, Carlsbad Tech, GlaxoSmithKline PLC, Zydus Cadila, Epi Health LLC, Viatris Inc., Apotex Inc., Teva Pharmaceuticals Industries Ltd., and Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global herpes simplex virus treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herpes simplex virus treatment market.

Detailed Segmentation:

  • Global Herpes Simplex Virus Treatment Market By Drug Type:
    • Acyclovir
    • Valacyclovir
    • Famciclovir
    • Other Drugs
  • Global Herpes Simplex Virus Treatment Market By Route of Administration:
    • Oral
    • Injection
    • Topical
  • Global Herpes Simplex Virus Treatment Market By Geography:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles:
    • Fresenius SE & Co. KgaA
    • Glenmark Pharmaceuticals
    • Carlsbad Tech
    • GlaxoSmithKline PLC
    • Zydus Cadila
    • Epi Health LLC
    • Viatris Inc.
    • Apotex Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)
Product Code: CMI5631

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in prevalence of infections of the herpes simplex virus
    • Social stigma about sexually transmitted diseases (STDs)
    • Increase in demand for safe and effective HSV therapeutics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Herpes Simplex Virus Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Herpes Simplex Virus Treatment Market, By Drug Type, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Acyclovir
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Valacyclovir
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Famciclovir
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Other Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Herpes Simplex Virus Treatment Market, By Route of Administration, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Herpes Simplex Virus Treatment Market, By Geography, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)

8. Competitive Landscape

  • Fresenius SE & Co. KgaA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Glenmark Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Carlsbad Tech
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Zydus Cadila
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Epi Health LLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Viatris Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Apotex Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceuticals Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!